QUANTITATIVE ESTIMATE has-miR-16-5p, has-miR-425-5p, has-miR-17-5p, has-miR-20a-5p, has-miR-101-3p, has-miR-30D-5p AND has-miR-93-5p IN PERIPHERAL BLOOD PLASMA OF WOMEN AS METHOD FOR NON-INVASIVE DIAGNOSIS OF SEROUS BOUNDARY OVARY ADENOCYSTOMA AND CYSTADENOCARCENOMA Russian patent published in 2019 - IPC G01N33/574 C12Q1/68 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to oncogynecology, and aims at non-invasive diagnosis of serous adenocystoma borderline and high-grade ovarian cystadenocarcinoma. Disclosed is a quantitative estimate of hsa-miR-16-5p, hsa-miR-425-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-101-3p, hsa-miR-30d-5p and hsa-miR-93-5p in peripheral blood plasma of females. Quantitative real-time PCR in a blood plasma sample of a woman is used to determine the level of expression of seven mRNA (hsa-miR-16-5p, hsa-miR-425-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-101-3p, hsa-miR-30d-5p and hsa-miR-93-5p) with preferable use of standard DNA for subsequent calculation of the estimation parameter (EP) when constructing the PLS-DA model. If value is 0 < EP <4.5, a high probability of having a serous ovarian tumour in a woman (serous border cystadene and serous cystadenocarcinoma of high degree of malignancy) is stated. If the value is -1.8 <0 <0, a high probability of serous ovarian tumour absence is stated.

EFFECT: invention provides differential diagnosis of serous ovarian tumours with high accuracy and diagnostic significance.

1 cl, 12 dwg, 2 ex